{"id":"cit-013-high-dose","safety":{"commonSideEffects":[{"rate":"0.1-1.0%","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"1.0-5.0%","effect":"Increased risk of genital yeast infections"},{"rate":"1.0-5.0%","effect":"Increased risk of hypotension"},{"rate":"0.1-1.0%","effect":"Increased risk of acute kidney injury"}]},"_chembl":{"chemblId":"CHEMBL3979793","moleculeType":"Small molecule","molecularWeight":"476.41"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, CIT-013 high dose reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and subsequent lowering of blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The exact molecular details of CIT-013 high dose's interaction with the SGLT2 receptor are not well understood.","oneSentence":"CIT-013 high dose is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:54.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06567470","phase":"PHASE2","title":"A Study With CIT-013 in RA Patients","status":"RECRUITING","sponsor":"Citryll BV","startDate":"2025-07-29","conditions":"Rheumatoid Arthritis","enrollment":88},{"nctId":"NCT06993233","phase":"PHASE2","title":"A Study With CIT-013 in HS Patients","status":"RECRUITING","sponsor":"Citryll BV","startDate":"2025-10-31","conditions":"Hidradenitis Suppurativa (HS)","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CIT-013 high dose","genericName":"CIT-013 high dose","companyName":"Citryll BV","companyId":"citryll-bv","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CIT-013 high dose is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}